| Primary |
| Hodgkin's Disease |
55.0% |
| Testis Cancer |
11.5% |
| Testicular Germ Cell Cancer |
4.1% |
| Diffuse Large B-cell Lymphoma |
3.5% |
| Lymphoma |
3.2% |
| Non-hodgkin's Lymphoma |
3.1% |
| Ovarian Cancer |
3.1% |
| Germ Cell Cancer |
2.7% |
| Hodgkin's Disease Mixed Cellularity Stage Iv |
1.9% |
| B-cell Lymphoma |
1.7% |
| Testicular Germ Cell Cancer Metastatic |
1.4% |
| Cervix Carcinoma |
1.3% |
| Chemotherapy |
1.2% |
| Hodgkin's Disease Stage Iv |
1.2% |
| Yolk Sac Tumour Site Unspecified |
1.0% |
| Burkitt's Lymphoma |
0.9% |
| Craniopharyngioma |
0.9% |
| Product Used For Unknown Indication |
0.9% |
| Seminoma |
0.9% |
| Gestational Trophoblastic Tumour |
0.8% |
|
| Dermatitis |
15.9% |
| Hypothyroidism |
9.1% |
| Neutropenia |
8.3% |
| Pulmonary Fibrosis |
7.6% |
| Spermatogenesis Abnormal |
6.8% |
| Respiratory Disorder |
5.3% |
| Scleroderma |
5.3% |
| Acute Myeloid Leukaemia |
3.8% |
| Febrile Neutropenia |
3.8% |
| Osteonecrosis |
3.8% |
| Pyrexia |
3.8% |
| Sepsis |
3.8% |
| Acute Lymphocytic Leukaemia |
3.0% |
| Autoimmune Thrombocytopenia |
3.0% |
| Cerebrovascular Disorder |
3.0% |
| Interstitial Lung Disease |
3.0% |
| Pulmonary Toxicity |
3.0% |
| Pulmonary Veno-occlusive Disease |
3.0% |
| Anaemia |
2.3% |
| Brain Neoplasm |
2.3% |
|
| Secondary |
| Hodgkin's Disease |
49.9% |
| Diffuse Large B-cell Lymphoma |
9.9% |
| Lymphoma |
7.9% |
| T-cell Lymphoma |
3.9% |
| Testis Cancer |
3.5% |
| Germ Cell Cancer |
3.3% |
| Non-hodgkin's Lymphoma |
3.2% |
| Product Used For Unknown Indication |
3.2% |
| Drug Use For Unknown Indication |
2.5% |
| Peripheral T-cell Lymphoma Unspecified |
1.8% |
| B-cell Lymphoma |
1.4% |
| Ovarian Cancer |
1.3% |
| Chemotherapy |
1.3% |
| Seminoma |
1.1% |
| Testicular Germ Cell Cancer |
1.1% |
| Non-hodgkin's Lymphoma Stage Iv |
1.0% |
| Hodgkin's Disease Stage Iii |
1.0% |
| Prophylaxis |
0.9% |
| Choriocarcinoma |
0.9% |
| Ovarian Germ Cell Cancer |
0.8% |
|
| Pulmonary Toxicity |
12.5% |
| Toxicity To Various Agents |
12.3% |
| Metastasis |
9.5% |
| Thrombocytopenia |
6.7% |
| Pulmonary Embolism |
5.5% |
| Sepsis |
4.6% |
| Myelodysplastic Syndrome |
4.2% |
| Febrile Neutropenia |
4.0% |
| Infection |
4.0% |
| Neutropenia |
3.9% |
| Death |
3.7% |
| Hodgkin's Disease Recurrent |
3.7% |
| Respiratory Disorder |
3.7% |
| Myocardial Infarction |
3.3% |
| Vomiting |
3.3% |
| Hepatotoxicity |
3.2% |
| Polyneuropathy |
3.0% |
| Progressive Multifocal Leukoencephalopathy |
3.0% |
| Pyrexia |
3.0% |
| Cerebrovascular Accident |
2.8% |
|
| Concomitant |
| Hodgkin's Disease |
19.1% |
| Chemotherapy |
15.4% |
| Product Used For Unknown Indication |
11.8% |
| Non-hodgkin's Lymphoma |
6.6% |
| Prophylaxis |
5.9% |
| Drug Use For Unknown Indication |
5.6% |
| Eczema |
5.0% |
| Diffuse Large B-cell Lymphoma |
4.0% |
| Hiv Infection |
3.8% |
| Pseudolymphoma |
3.5% |
| Testis Cancer |
3.4% |
| Neutropenia |
2.8% |
| Anaemia Haemolytic Autoimmune |
2.7% |
| B-cell Lymphoma |
2.1% |
| Germ Cell Cancer |
1.9% |
| Non-hodgkin's Lymphoma Metastatic |
1.8% |
| Peripheral T-cell Lymphoma Unspecified |
1.6% |
| Cardiac Disorder |
1.2% |
| Dermatitis |
0.9% |
| Testicular Neoplasm |
0.9% |
|
| Febrile Neutropenia |
12.0% |
| Neutropenia |
7.0% |
| Pulmonary Toxicity |
7.0% |
| Pyrexia |
7.0% |
| Sepsis |
6.0% |
| Vomiting |
6.0% |
| White Blood Cell Count Increased |
6.0% |
| Pain |
5.0% |
| Syncope |
5.0% |
| Pneumonitis |
4.0% |
| Progressive Multifocal Leukoencephalopathy |
4.0% |
| Septic Shock |
4.0% |
| Vasogenic Cerebral Oedema |
4.0% |
| Weight Decreased |
4.0% |
| White Blood Cell Count Decreased |
4.0% |
| Agranulocytosis |
3.0% |
| Anaphylactic Reaction |
3.0% |
| Drug Ineffective |
3.0% |
| Dyspnoea |
3.0% |
| Neurotoxicity |
3.0% |
|
| Interacting |
| Product Used For Unknown Indication |
46.7% |
| Chemotherapy |
20.0% |
| Hiv Infection |
20.0% |
| Diffuse Large B-cell Lymphoma |
13.3% |
|
| Diarrhoea |
66.7% |
| Bone Marrow Failure |
16.7% |
| Fat Embolism |
16.7% |
|
